摘要
目的:探讨吲哚美辛肠溶片与布洛芬口服治疗早产儿动脉导管未闭(patent ductus arteriosus,PDA)的疗效及对血清游离胆固醇(FC)、血清肌钙蛋白T(cTnT)、磷酸肌酸激酶杂化型(CK-MB)水平的影响。方法:选取2016年6月-2019年6月本院80例PDA早产儿,按随机数字表法分为对照组和试验组,每组各40例。对照组进行吲哚美辛肠溶片口服治疗,试验组进行布洛芬口服治疗。比较两组PDA关闭率、血清FC、cTnT、CK-MB水平及不良反应发生情况。结果:试验组PDA关闭率(97.50%)与对照组(95.00%)比较,差异无统计学意义(P>0.05)。两组治疗前后血清FC、cTnT及CK-MB水平比较,差异均无统计学意义(P>0.05);两组治疗后血清FC、cTnT及CK-MB水平均明显低于治疗前(P<0.05)。试验组不良反应发生率为7.50%明显低于对照组的32.50%(P<0.05)。结论:吲哚美辛肠溶片与布洛芬口服均可促进PDA早产儿动脉导管闭合,疗效显著,但口服布洛芬不良反应更少,安全性更高。
Objective:To investigate the effect of Indomethacin Enteric-coated Tablets and Ibuprofen oral therapy on premature infants with patent ductus arteriosus(PDA)and its effect on serum free cholesterol(FC),troponin T(cTnT)and phosphocreatine kinase hybridized type(CK-MB).Method:From June 2016 to June 2019,80 premature infants with PDA in our hospital were selected.According to the random number table method,they were divided into the control group and the experimental group,40 cases in each group.The control group was treated with oral therapy of Indomethacin Enteric-coated Tablets,and the experimental group was treated with oral therapy of Ibuprofen.PDA closure rate,serum FC,cTnT,CK-MB levels and adverse reactions were compared between the two groups.Result:The PDA closure rate of the experimental group(97.50%)was compared with that of the control group(95.00%),the difference was not statistically significant(P>0.05).There were no statistically significant differences in the levels of serum FC,cTnT and CK-MB in the two groups before and after treatment(P>0.05).The levels of serum FC,cTnT and CK-MB in the two groups after treatment were significantly lower than before treatment(P<0.05).The incidence of adverse reactions in the experimental group was 7.50%significantly lower than 32.50%in the control group(P<0.05).Conclusion:Indomethacin Enteric-coated Tablets and Ibuprofen oral therapy can promote the closure of ductus arteriosus in premature infants with PDA,with significant efficacy.But oral Ibuprofen has fewer adverse reactions and is safer.
作者
梁颖娜
包莉娜
李立新
LIANG Yingna;BAO Li’na;LI Lixin(Baiyun Maternal and Child Health Hospital,Guangzhou 510400,China;不详)
出处
《中国医学创新》
CAS
2020年第10期53-56,共4页
Medical Innovation of China
基金
广州市白云区2016年度科技计划项目(2016-KZ-040)。
关键词
早产儿动脉导管未闭
布洛芬
吲哚美辛肠溶片
Premature infants with patent ductus arterioides
Ibuprofen
Indomethacin Enteric-coated Tablets
